Compare Sana Biotechnology Inc (SANA) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs BlackRock TCP Capital Corp — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while BlackRock TCP Capital Corp trades at $4.03 (market cap $337.71M). The key difference: Sana Biotechnology Inc is far larger — about 2.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and BlackRock TCP Capital Corp for 88 Days on average.
| SANA | TCPC | |
|---|---|---|
Market Cap | $836.71M | $337.71M |
Volume | 4,507,444 | 436,109 |
Sector | Health | Financials |
52-Week High | $5.92 | $6.20 |
52-Week Low | $2.68 | $3.13 |
Typical Hold Time | 23 Days | 88 Days |
Enterprise Value | $749.96M | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
TCPC trades at $4.035, up 2.41% today, with a bullish technical signal supported by moving averages. The company reported mixed earnings with Q2 2026 beating estimates but faces negative revenue and net income trends. Recent portfolio sales and strategic reviews aim to reduce leverage and enhance shareholder value. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
Outlook remains cautious due to declining revenue and negative profitability metrics, though strategic moves may stabilize operations. Key risks include ongoing financial losses and competitive pressures in the BDC sector. Investment opportunity hinges on successful execution of portfolio optimization and debt reduction initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
